NAD(P)H:Quinone oxidoreductase 1 (NQO1) Pro187Ser polymorphism and colorectal cancer predisposition in the ethnic Kashmiri population

Asian Pacific Journal of Cancer Prevention

Volumn 11, Issue 1, 2010, Pages 209-213

  Sameer, A Syed ^a   Shah, Zaffar A ^a   Syeed, Nidda ^a   Abdullah, Safiya ^a   Rasool, Roohi ^a   Afroze, Dil ^a   Siddiqi, Mushtaq A ^a  

^a SHER I KASHMIR INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Colorectal cancer; Kashmir; NQO1; Polymorphism; Restriction digestion; RFLP

Indexed keywords

NQO1 PROTEIN, HUMAN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE);

ADENOCARCINOMA; CASE CONTROL STUDY; COLORECTAL TUMOR; COMPARATIVE STUDY; FEMALE; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; HUMAN; INDIA; MALE; MIDDLE AGED; PATHOLOGY; POLYMERASE CHAIN REACTION; PROGNOSIS; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; SQUAMOUS CELL CARCINOMA;

ADENOCARCINOMA; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INDIA; MALE; MIDDLE AGED; NAD(P)H DEHYDROGENASE (QUINONE); POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; RISK FACTORS;

EID: 77955797111     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Begleiter A, Hewitt D, Maksymiuk AW, Ross DA, Bird RP (2006). A NAD(P)H:quinone oxidoreductase 1 polymorphism is a risk factor for human colon cancer. Cancer Epidemiol Biomarkers Prev, 15, 2422-6.
2. Begleiter A, Sivananthan K, Curphey TJ, Bird RP (2003). Induction of NAD(P)H quinone:oxidoreductase1 inhibits carcinogen induced aberrant crypt foci in colons of Sprague-Dawley rats. Cancer Epidemiol Biomarkers Prev, 12, 566-72.
3. Center MM, Jemal A, Smith A, Ward E (2009). Worldwide variations in colorectal cancer. CA Cancer J Clin, 59, 366-378.
4. Center MM, Jemal A, Ward E (2009). International trends in colorectal cancer incidence rates. Cancer Epidemiol Biomarkers Prev, 18, 1688-694.
5. Chao C, Zhang Z-F, Berthiller J, Boffetta P, Hashibe M (2006). NAD(P)H:Quinone Oxidoreductase 1 (NQO1) Pro187Ser polymorphism and the risk of lung, bladder, and colorectal cancers: a meta-analysis. Cancer Epidemiol Biomarkers Prev, 15, 979-987
6. Chen H, Lum A, Seifried A, Wilkens LR Marchand LL (1999). Association of the NAD(P)H:quinone oxidoreductase 609C3T polymorphism with a decreased lung cancer risk Cancer Res, 59, 3045-8.
7. Chen S, Wu K, Knox R (2000). Structure-function studies of DT-diaphorase (NQO1) and NRH:quinone oxidoreductase (NQO2). Free Rad Biol Med, 29, 276-84.
8. Felton JS, Knize MG (1991). Occurrence, identification, and bacterial mutagenicity of heterocyclic amines in cooked food. Mutat Res, 259, 205-17.
9. Hou L, Chatterjee N, Huanh W-Y, et al (2005). CYP1A1 Val462 and NQO1 Ser187 polymorphisms, cigarette use, and risk for colorectal adenoma. Carcinogenesis, 26, 1122-8.
10. Joseph P. Jaiswal AK (1994). NAD(P)H:quinone oxidoreductase1 (DT diaphorase) specifically prevents the formation of benzo[a]pyrene quinone--DNA adducts generated by cytochrome P4501A1 and P450 reductase. Proc Natl Acad Sci USA, 91, 8413-7.
11. Kelsey KT, Ross D, Traver RD, et al (1997). Ethnic variation in the prevalence of a common NAD(P)H quinone oxidoreductase polymorphism and its implications for anticancer chemotherapy. Br J Cancer, 76, 852-4.
12. Krajinovic M, Sinnett H, Richer C, Labuda D, Sinnett D (2002). Role of NQO1, MPO and CYP2E1 genetic polymorphisms in the susceptibility to childhood acute lymphoblastic leukemia. Int J Cancer, 97, 230-6.
13. Lafuente MJ, Casterad X, Trias M, et al (2000). NAD(P)H: quinone oxidoreductasedependent risk for colorectal cancer and its association with the presence of K-ras mutations in tumors. Carcinogenesis, 21, 1813-9.
14. Menze H-J, Sarmanova J, Soucek P, et al (2004). Association of NQO1 polymorphism with spontaneous breast cancer in two independent populations. Br J Cancer, 90, 1989-94.
15. Mir MM, Dar NA, Gochhait S, Zargar SA, et al (2005). p53 Mutation profile of squamous cell carcinomas of the esophagus in Kashmir (India): a high-incidence area. Int J Cancer, 116, 62-8.
16. Mitrou PN, Watson MA, Loktionov AS, et al (2007). Role of NQO1C609T and EPHX1 gene polymorphisms in the association of smoking and alcohol with sporadic distal colorectal adenomas: results from the UKFSS Study. Carcinogenesis, 28, 875-82.
17. Murtaza I, Mushtaq D, Margoob MA, Dutt A, et al (2006). A study on p53 gene alterations in esophageal squamous cell carcinoma and their correlation to common dietary risk factors among population of the Kashmir valley. World J Gastroenterol, 12, 4033-7.
18. Naoe T, Takeyama K, Yokozawa T, et al (2000). Analysis of genetic polymorphism in NQO1, GST-M1, GST-T1, and CYP3A4in 469 Japanese patients with therapy-related leukemia/myelodysplastic syndrome and de novo acute myeloid leukemia. Clin Cancer Res, 6, 4091-5.
19. Park S-J, Zhao H, Spitz MR, Grossman HB, Wu X (2003). An association between NQO1 genetic polymorphism and risk of bladder cancer. Mutat Res, 536, 131-7.
20. Parkinson A (2003). Biotransformation of Xenobiotics. In Klaussen,C. (ed.), Casarett and Doull's Toxicology: The Basic Science of Poisons. McGraw--Hill, New York, pp. 133-237.
21. Ross D (2004). NQO1. Atlas Genet Cytogenet Oncol Haematol.. URL : http://AtlasGeneticsOncology.org/Genes/NQO1ID375.html
22. Sameer AS, Rehman S, Pandith AA, et al (2009). Molecular gate keepers succumb to gene aberrations in colorectal cancer in Kashmiri population, revealing a high incidence area. Saudi J Gastroenterol, 15, 244-52.
23. Sameer AS, Shah ZA, Syeed N, et al (2010). TP53 Pro47Ser and Arg72Pro polymorphisms and colorectal cancer predisposition in the ethnic Kashmiri population. Genet Mol Res, 9, 651-60.
24. Sarbia M, Bitzer M, Siegel D, et al (2003). Association between NAD(P)H:quinine oxidoreductase 1 (NQ01) inactivating C609T polymorphism and adenocarcinoma of the upper gastrointestinal tract. Int J Cancer, 107, 381-6.
25. Schulz WA, Krummeck A, Rosinger I, et al (1997). Increased frequency of a nullallele for NAD(P)H:quinone oxidoreductase in patients with urological malignancies. Pharmacogenetics, 7, 235-9.
26. Siddiqi M, Kumar R, Fazili Z, Spiegelhalder B, et al (1992). Increased exposure to dietary amines and nitrate in a population at high risk of esophageal and gastric cancer in Kashmir (India). Carcinogenesis, 13, 1331-5.
27. Siegel D, Gustafson DL, Dehn DL, et al (2004). NAD(P)H: quinone oxidoreductase 1: role as a superoxide scavenger. Mol Pharmacol, 65, 1238-47.
28. Siegel D, McGuinness SM, Winski SL, Ross D (1999). Genotypephenotype relationships in studies of a polymorphism in NAD(P)H:quinone oxidoreductase 1. Pharmacogenetics, 9, 113-21.
29. Sivananthan K, Bird RP, Maksymiuk AW, Lefas G, Begleiter A (2005). Effect of post-initiation induction of NQO1 by oltipraz on AOM induced colon tumor formation in Sprague-Dawley rats. Proc Am Assoc Cancer Res, 46, 581.
30. Smith MT, Wang Y, Kane E, et al (2001). Low NAD(P)H: quinone oxidoreductase 1 activity is associated with increased risk of acute leukemia in adults. Blood, 97, 1422-6.
31. Van der Logt EMJ, Bergevoet SM, Roelofs HMJ, et al (2006). Role of epoxide hydrolase, NAD(P)H:quinone oxidoreductase, cytochrome P450 2E1 or alcohol dehydrogenase genotypes in susceptibility to colon cancer. Mutat Res, 593, 39-49.
32. Wiemels JL, Pagnamenta A, Taylor GM, et al (1999). A lack of a functional NAD(P)H:quinone oxidoreductase allele is selectively associated with pediatric leukemias that have MLL fusions. Cancer Res, 59, 4095-9.
33. Winski SL, Koutalos Y, Bentley DL, Ross D (2002). Subcellular localization of NAD(P)H: quinone oxidoreductase 1 inhuman cancer cells. Cancer Res, 62, 1420-4.
34. Zhang J-H, Li Y, Wang R, et al (2003). NQO1 C609T polymorphism associated with esophageal cancer and gastric cardiac carcinoma in North China. World J Gastroenterol, 9, 1390-3.